Multimodal Control of STAT6 Signaling through Small-Molecule Modulation and Targeted Degradation

Recent patent disclosures from Gilead Sciences reveal a coordinated, multimodal strategy to control STAT6 signaling therapeutically. Small-molecule modulators provide tunable, tissue-focused pathway attenuation, while heterobifunctional degraders enable more profound and potentially more durable suppression. Together, these inventions define STAT6 as a context-sensitive target whose optimal intervention depends on disease biology, exposure, and required depth of pathway control.